Retrospective study examined the efficacy and safety of brentuximab vedotin for treatment of relpased Hodgkin lymphoma following stem cell transplant.
Home / Resource Library / Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation